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Antenatal 
corticosteroids to 
reduce preterm deaths 
in low-income settings
Authors’ reply
We agree with many of the 
correspondents’ points. First, we 
concur that antenatal corticosteroid 
treatment can reduce respiratory 
distress in infants born at less than 
34 weeks’ gestation. Second, we 
welcome the rapid scale-up of its use 
in hospitals in Malawi, as described 
by Stephen Kaliti, and look forward 
to the published assessment of 
its effect on mortality in preterm 
infants. Third, we agree that more 
research is needed to explore the best 
methods for scale-up in hospitals and 
to assess the risks and benefits to 
patients through community studies 
in low-income regions. Particularly, 
we anticipate findings of a trial of 
antenatal corticosteroid treatment 
that is underway in several countries 
and in which 90 000 infants have 
been enrolled. 
Conversely, we are not in agree-
ment with Joy Lawn and colleagues 
who suggest that it is, “extremely 
unlikely, statistically, that antenatal 
corticosteroids would be shown not 
to work in African or Asian babies”. 
Our point about the potential 
risks associated with antenatal 
corticosteroid scale-up was not a 
question of efficacy, or ethnicity, 
but instead the underlying risks and 
beneﬁ ts of antenatal corticosteroids 
to populations in low-income 
regions and diﬀ erent levels of access 
to health care. These factors can 
strikingly change the beneﬁ t-to-risk 
ratio of interventions. For example, 
in low-income regions in south 
Asia and Africa, dietary vitamin A 
supplementation in rural populations 
and participatory women’s groups 
had a large eﬀ ect on child survival, but 
there is no evidence of a similar eﬀ ect 
in populations in high-income regions 
in the USA or Europe.1,2 
Our concern arose  because of 
reports implying that antenatal 
corticosteroids could be scaled up as 
a vertical treatment  administered to 
women with signs of preterm labour 
by community health-care workers, or 
at outreach clinics without specialised 
level-2 health-care facilities. Two 
potential risks from this setting could 
outweigh the beneﬁ ts: the possibility 
that the number needed to treat, to 
save the life of a preterm infant, could 
increase the incidence of serious 
sepsis in mothers, and second, death 
or disability might occur later as a 
result of suboptimal preterm care. 
Globally, 40 million women deliver 
their babies at home every year and 
many more face formidable economic, 
cultural, and geographical barriers 
to accessing good-quality maternity 
health care. Many of these women 
live in low-income regions and rural 
populations in Africa and south Asia 
and endure high levels of malnutrition, 
especially a lack of micronutrients 
and protein, malaria, anaemia, and 
worm infestations that combined 
with the immunosuppressive effect 
of pregnancy or HIV infection might 
increase their vulnerability to sepsis. 
In the USA, chorioamnionitis aﬀ ects 
9% of pregnancies, but the burden 
of placental infection is much higher 
in Africa and Asia.3,4 We agree with 
Caroline Crowther and Julie Brown 
that a paucity of evidence exists for 
the effect of dexamethasone on 
maternal infection, anywhere, and a 
complete absence of evidence exists 
in low-income settings. Health-care 
workers need to be sure, however, 
that antenatal corticosteroids do 
not exacerbate the severity, or the 
dissemination, of maternal infections 
in these communities. 
Stephen Kaliti suggests that, 
“antenatal corticosteroids are likely to 
have a greater eﬀ ect in the absence of 
level 2 care, not a lesser eﬀ ect”, but the 
evidence to support this statement is 
weak. Any policy to extend antenatal 
corticosteroid delivery to mothers 
through community health-care 
workers in regions where access to 
good-quality specialised care is not 
available (and where the assessment 
of gestational age and duration 
of pregnancy is often unreliable) 
should be on the basis of randomised 
community effectiveness trials. 
The risks and benefits can then be 
measured in the same way that those 
of dietary vitamin A, chlorhexidine, 
and zinc supplementation have been 
assessed in populations in low-income 
regions.5,6 We urge funders to support 
these studies.
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